AmorChem has formed of Corbin Therapeutics Inc., its third spin-off company focusing on a novel therapeutic approach to treat various inflammation-based diseases via inhibition of the ubiquitin carboxyl-terminal hydrolase 15 (USP15) enzyme.
AmorChem has transferred all rights to the USP15 technology together with $1 million seed funding to Corbin. The spinoff was completed in October 2016.
Dr. Maxime Rangeras has been appointed as CEO and a director of Corbin. Crobin’s board also includes Dr. Elizabeth Douville, Managing Partner of AmorChem.
The USP15 technology has been developed in the laboratory of Dr. Philippe Gros who will serves as scientific advisor.
photo credit: AmorChem
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- Praemo secures $3.5M Series A led by McRock Capital - August 22, 2019
- Drop announces US $44M Series B led by HOF Capital - August 22, 2019
- H1 2019 – Owen Bird and Torys leading law firms in exempt financing - August 21, 2019